Tuberculosis (TB) is the deadliest infectious disease worldwide. The design of new
treatments for TB is hindered by the large number of candidate drugs, drug combinations …

The rapid spread of multidrug-resistant strains has created a pressing need for new drug
regimens to treat tuberculosis (TB), which kills 1.8 million people each year. Identifying new …

Combination therapy has, to some extent, been successful in limiting the emergence of drug-
resistant tuberculosis. Drug combinations achieve this advantage by simultaneously acting …

There is an urgent need for new drug regimens to rapidly cure tuberculosis. Here, we report
the development of drug response assayer (DRonA) and" MLSynergy," algorithms to …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Tuberculosis is one of the deadliest infectious diseases worldwide and the prevalence of
latent tuberculosis acts as a huge roadblock in the global effort to eradicate tuberculosis …

Highlights•Dose selection for new combination therapy in tuberculosis has remained
empirical.•Novel tools are needed for effective translation of preclinical models to humans.•A …

We report a computational approach that integrates structural bioinformatics, molecular
modelling and systems biology to construct a drug-target network on a structural proteome …

Host-directed therapies (HDTs) that modulate host–pathogen interactions offer an innovative
strategy to combat Mycobacterium tuberculosis (Mtb) infections. When combined with …